Neuropharmacology of addiction and how it informs treatment

British Medical Bulletin

Volumn 96, Issue 1, 2010, Pages 93-110

  Lingford Hughes, Anne ^a   Watson, Ben ^b   Kalk, Nicola ^a,b   Reid, Alastair ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

addiction; alcohol; neuropharmacology; nicotine; opioid; treatment

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; CENTRAL STIMULANT AGENT; CLONIDINE; COCAINE; DELTA OPIATE RECEPTOR; DIAMORPHINE; DISULFIRAM; DOPAMINE; KAPPA OPIATE RECEPTOR; LOFEXIDINE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; OPIATE; UNINDEXED DRUG; VARENICLINE;

ALCOHOLISM; AMYGDALOID NUCLEUS; ANALGESIA; DESENSITIZATION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERANCE; HUMAN; MAINTENANCE THERAPY; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVE CELL NETWORK; NEUROBIOLOGY; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PHARMACOGENETICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUPIL REFLEX; RELAPSE; RESPIRATION DEPRESSION; REVIEW; REWARD; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE; DRUG TOLERANCE; HUMANS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 78649668074     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq032     Document Type: Review

References (67)

1. WHO. The Global Burden of Disease, 2004 Update. Geneva, World Health Organization, 2008.
2. NHS Information Centre, Lifestyle Statistics. Statistics on Alcohol: England, 2009. UK: Health and Social Care Information Centre, 2009.
3. Singleton N, Murray R, Tinsley L. Measuring different aspects of problem drug use: methodological developments. Home office online report 16/06.
4. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001;24:97-129.
5. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J Clin Invest 2003;111:1444-51.
6. Montgomery AJ, Lingford-Hughes AR, Egerton A et al. The effect of nicotine on striatal dopamine release in man: a [11C]raclopride PET study. Synapse 2007;61:637-45.
7. Boileau I, Assaad JM, Pihl RO et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003;49:226-31.
8. Daglish MR, Williams TM, Wilson SJ et al. Brain dopamine response in human opioid addiction. Br J Psychiatry 2008;193:65-72.
9. Volkow ND, Wang GJ, Fowler JS et al. Prediction of reinforcing responses to psychostimu-lants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999;156:1440-3.
10. Morgan D, Grant KA, Gage HD et al. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 2002;5:169-74.
11. Nader MA, Morgan D, Gage HD et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006;9:1050-6.
12. Dalley JW, Fryer TD, Brichard L et al. Nucleus accumbens D2/3 receptors predict trait impul-sivity and cocaine reinforcement. Science 2007;315:267-70.
13. Boileau I, Dagher A, Leyton M et al. Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J Neurosci 2007;27:3998-4003.
14. Volkow ND, Fowler JS, Wang GJ et al. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009;56:3-8.
15. Narendran R, Martinez D. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse 2008;62:851-69.
16. Nader MA, Czoty PW, Gould RW et al. Positron emission tomography imaging studies of dopamine receptors in primate models of addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3223-32.
17. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-37.
18. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001;7:293-302.
19. Volkow ND, Wang GJ, Telang F et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006;26:6583-8.
20. Zijlstra F, Booij J, Van Den Brink W et al. Striatal dopamine D2 receptor binding and dopa-mine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 2008;18:262-70.
21. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits. Nature Neuroscience 2005;8:1481-9.
22. Everitt BJ, Belin D, Economidou D et al. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3125-5.
23. Newton TF, Roache JD, De La Garza R et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-44.
24. Elkashef AM, Rawson RA, Anderson AL et al. Buproprion for the treatment of methadone dependence. Neuropsychopharmacology 2008;33:1162-70.
25. Reichel CM, Murray JE, Grant KM et al. Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 2009;100:54-62.
26. Heidbreder CA, Gardner EL, Xi ZX et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 2005;49:77-105.
27. Lawford BR, Young RM, Rowell JA et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1995;1:337-41.
28. Carroll KM, Nich C, Ball SA et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93:713-27.
29. Cousins MS, Roberts DC, de Wit H. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002;65:209-20.
30. Filip M, Frankowska M. GABA(B) receptors in drug addiction. Pharmacol Rep 2008;60:755-0.
31. Johnson BA. Recent adVances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005;19:873-96.
32. Addolorato G, Leggio L, Ferrulli A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915-22.
33. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009;36:S15-23.
34. Kahn R, Biswas K, Childress AR et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009;103:59-64.
35. Franklin TR, Harper D, Kampman K et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009;103:30-6.
36. Heinzerling KG, Shoptaw S, Peck JA et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:177-84.
37. Le Merrer J, Becker JA, Befort K et al. Reward processing by the opioid system in the brain. Physiol Rev 2009;89:1379-412.
38. Gorelick DA, Kim YK, Bencherif B et al. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 2005;57:1573-82.
39. Williams TM, Daglish MR, Lingford-Hughes A et al. Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. Br J Psychiatry 2007;191:63-9.
40. Williams TM, Davies SJ, Taylor LG et al. Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol 2009;19:740-8.
41. Olmstead MC, Ouagazzal AM, Kieffer BL. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS One 2009;4:e4410.
42. Boettiger CA, Kelley EA, Mitchell JM et al. Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav 2009;93:291-9.
43. Volpicelli JR. Naltrexone in alcohol dependence. Lancet 1995;346:456.
44. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005;CD001867.
45. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psych 2005;162:1403-13.
46. Baker DA, McFarland K, Lake RW et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature Neuroscience 2003;6:743-9.
47. LaRowe SD, Myrick MD, Hedden S et al. Is cocaine desire reduced by N-acetylcysteine?. Am J Psychiatry 2007;164:1115-7.
48. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32:1105-0.
49. Verheul R, Lehert P, Geerlings PJ et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005;178:167-73.
50. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001;81:299-343.
51. Krystal JH, Staley J, Mason G et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 2006;63:957-68.
52. Krystal JH, Petrakis IL, Krupitsky E et al. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 2003;1003:176-84.
53. Markou A. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 2008;363:3159-68.
54. Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: and update on addictive properties. Handb Exp Pharmacol 2009;192:335-67.
55. Balfour DJK. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 2009;192:209-33.
56. Krupitsky EM, Rudenko AA, Burakov AM et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007;31:604-11.
57. De Witte P, Littleton J, Parot P et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-37.
58. Thomson AD, Cook CC, Guerrini I et al. Wernicke's encephalopathy: 'Plus ça change, plus c'est la mème chose'. Alcohol Alcohol 2008;43:180-6.
59. Lingford-Hughes AR, Welch S, Nutt DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004;18:293-335.
60. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacother-apy. Expert Opin Pharmacother 2009;10:1727-40.
61. 18F] cyclofoxy in long-term, methadone-treated, former heroin addicts. J Pharmacol Exp Therapeut 2000;295:1070-6.
62. Melichar JK, Hume SP, Williams TM et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 2005;312:309-15.
63. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009;69:577-607.
64. Greenwald MK, Johanson CE, Moody DE et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9.
65. Crunell CL, Miller ML, Booij J et al. The nicotinic acetylcholine receptor partial agonist var-enicline and the treatment of drug dependence: A review. Eur Neuropsychopharm 2010;20:69-79.
66. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the m-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52.
67. Reid A, Lingford-Hughes A. Neuropharmacology of addiction. Psychiatry 2006;5:449-54.